Emergent BioSolutions Appoints Allen Shofe Vice President of Government Affairs

Sep 15, 2005, 01:00 ET from Emergent BioSolutions Inc.

    GAITHERSBURG, Md., Sept. 15 /PRNewswire/ -- Emergent BioSolutions Inc.
 today announced the appointment of Allen Shofe to the position of Vice
 President of Government Affairs.  In this position, Mr. Shofe will be
 responsible for designing, implementing and overseeing all aspects of the
 company's domestic and international government affairs initiatives.
     "Allen is a versatile and highly astute government relations and public
 affairs executive," said Fuad El-Hibri, CEO of Emergent BioSolutions.  "His
 government affairs expertise and extensive network of professional contacts
 throughout the United States and Europe will prove invaluable as we continue
 our efforts to become a global leader in our field."
     Mr. Shofe has more than 15 years experience in government relations and
 government affairs at the Federal and state levels, as well as in the
 international arena.  Mr. Shofe previously held the position of Director of
 Federal Government Relations at Eli Lilly and Company, where he managed a
 series of government initiatives, including those that focused on intellectual
 property, patent law and tort reform.  Mr. Shofe received his BA in
 International Relations/Diplomacy at the University of Minnesota and an LL.M,
 Master of Laws from the University of Leicester in the United Kingdom.
     "I look forward to the opportunity to help advance Emergent BioSolutions
 into a world class biopharmaceutical company," said Mr. Shofe.  "This company
 has such a promising future, and to be a part of its growth and success is
 something I am extremely proud of."
     About Emergent BioSolutions
     Emergent BioSolutions Inc., formed in 2004, is dedicated to the research,
 development and manufacture of novel products which harness the immune system
 to treat and prevent disease.  These include vaccines and related products for
 prophylactic and therapeutic use against common infectious diseases and
 biological weapons of mass destruction.  The company currently employs more
 than 450 people with facilities in Gaithersburg and Frederick, Maryland,
 Lansing, Michigan, Berkshire, U.K. and Munich Germany.  More information about
 Emergent BioSolutions and its subsidiaries can be found at http://www.ebsi.com

SOURCE Emergent BioSolutions Inc.